GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Olema Pharmaceuticals inc (NAS:OLMA) » Definitions » Cash Ratio

Olema Pharmaceuticals (Olema Pharmaceuticals) Cash Ratio : 12.11 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Olema Pharmaceuticals Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Olema Pharmaceuticals's Cash Ratio for the quarter that ended in Dec. 2023 was 12.11.

Olema Pharmaceuticals has a Cash Ratio of 12.11. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Olema Pharmaceuticals's Cash Ratio or its related term are showing as below:

OLMA' s Cash Ratio Range Over the Past 10 Years
Min: 0.05   Med: 14.01   Max: 73.84
Current: 12.11

During the past 6 years, Olema Pharmaceuticals's highest Cash Ratio was 73.84. The lowest was 0.05. And the median was 14.01.

OLMA's Cash Ratio is ranked better than
86.81% of 1524 companies
in the Biotechnology industry
Industry Median: 2.92 vs OLMA: 12.11

Olema Pharmaceuticals Cash Ratio Historical Data

The historical data trend for Olema Pharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olema Pharmaceuticals Cash Ratio Chart

Olema Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial 0.05 73.84 31.85 12.35 12.11

Olema Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.35 9.58 11.29 17.34 12.11

Competitive Comparison of Olema Pharmaceuticals's Cash Ratio

For the Biotechnology subindustry, Olema Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Olema Pharmaceuticals's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Olema Pharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Olema Pharmaceuticals's Cash Ratio falls into.



Olema Pharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Olema Pharmaceuticals's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=261.807/21.621
=12.11

Olema Pharmaceuticals's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=261.807/21.621
=12.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Olema Pharmaceuticals  (NAS:OLMA) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Olema Pharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of Olema Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Olema Pharmaceuticals (Olema Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
512, 2nd Street, 4th Floor, San Francisco, CA, USA, 94107
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
Executives
Cyrus Harmon director, officer: Chief Technology Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Paradigm Biocapital Advisors Lp 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10017
G. Walmsley Graham director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kovacs Shane William Charles officer: Ch. Operating & Financial Off. PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Naseem Zojwalla officer: Chief Medical Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Sean Bohen director, officer: President and CEO C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
David C. Myles officer: Chief Development Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Senai Asefaw 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Paradigm Biocapital International Fund Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Biotechnology Value Fund L P 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Paradigm Biocapital Advisors Gp Llc 10 percent owner 767 THIRD AVENUE, 17TH FLOOR, NEW YORK CITY NY 10017
Kinney Horn officer: Chief Business Officer C/O OLEMA PHARMACEUTICALS, INC., 512 2ND STREET, 4TH FLOOR, SAN FRANCISCO CA 94107
Yi Larson director C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116